AMICUS THERAPEUTICS, INC. (FOLD)

SEC fundamentals · as filed in 10-K FY2025, period ended Dec 31, 2025 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$949.9M
Stockholders' Equity
$274.2M
Cash & Equivalents
$214.0M
Long-Term Debt
$392.7M

as filed in 10-K FY2025, period ended Dec 31, 2025 · View filings on EDGAR ↗

In its 10-K for the period ended Dec 31, 2025, AMICUS THERAPEUTICS, INC. reported revenue of $634.2M, net income of -$27.1M, and total assets of $949.9M. Every figure below is taken directly from AMICUS THERAPEUTICS, INC.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2016–FY2025 · as reported

$634.2M$138.9M-$356.4M
FY2016FY2019FY2022FY2025
Revenue$634.2MNet income-$27.1M
FY2016 revenue
$5.0M
FY2025 revenue
$634.2M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$634.2M-$27.1M
FY2024$528.3M-$56.1M
FY2023$399.4M-$151.6M
FY2022$329.2M-$236.6M
FY2021$305.5M-$250.5M
FY2020$260.9M-$276.9M
FY2019$182.2M-$356.4M
FY2018$91.2M-$349.0M
FY2017$36.9M-$284.0M
FY2016$5.0M-$200.0M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KApr 27, 2026on EDGAR ↗
8-KApr 23, 2026on EDGAR ↗
8-KMar 3, 2026on EDGAR ↗
8-KFeb 20, 2026on EDGAR ↗
10-KFeb 20, 2026on EDGAR ↗
8-KJan 26, 2026on EDGAR ↗
8-KDec 19, 2025on EDGAR ↗
8-KNov 4, 2025on EDGAR ↗
10-QNov 4, 2025on EDGAR ↗
8-KJul 31, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Dec 31, 2025 · 10-K

Total Assets$949.9Msource ↗
Stockholders’ Equity$274.2Msource ↗
Cash & Equivalents$214.0Msource ↗
Long-Term Debt$392.7Msource ↗

Income Statement

10-K (annual) · period ended Dec 31, 2025

Revenue$634.2Msource ↗
Net Income-$27.1Msource ↗
Operating Income$32.8Msource ↗
Gross Profit$561.3Msource ↗
Cost of Revenue$72.9Msource ↗
R&D Expense$135.8Msource ↗

Per Share & Cash Flow

10-K (annual) · period ended Dec 31, 2025

EPS (diluted)$-0.09source ↗
EPS (basic)$-0.09source ↗
Shares Outstanding314.0Msource ↗
Cash from Operations$33.1Msource ↗
Cash from Financing$610,000source ↗
Cash from Investing-$46.4Msource ↗

Restatement history

Point-in-time

2 of 440 annual fact-keys were materially restated between filings: what AMICUS THERAPEUTICS, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches FOLD’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/FOLD

MCP tool: get_sec_fundamentals ticker=FOLD

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/FOLD/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=FOLD as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/FOLD/history

MCP tool: get_fundamentals_history ticker=FOLD

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/FOLD

MCP tool: get_financial_health ticker=FOLD

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.